Immunomedics Revenue and Competitors
Estimated Revenue & Valuation
- Immunomedics's estimated annual revenue is currently $34.6M per year.
- Immunomedics received $125.0M in venture funding in May 2017.
- Immunomedics's estimated revenue per employee is $288,042
- Immunomedics's total funding is $30M.
Employee Data
- Immunomedics has 120 Employees.
- Immunomedics grew their employee count by -8% last year.
Immunomedics's People
Name | Title | Email/Phone |
---|---|---|
1 | Associate VP, Process Development and Manufacturing | Reveal Email/Phone |
2 | Controller | Reveal Email/Phone |
3 | Director and Head Patient Experience and Advocacy | Reveal Email/Phone |
4 | Director Process Development | Reveal Email/Phone |
5 | Exec. Director, Head IT | Reveal Email/Phone |
6 | Senior Director, Pre-Clinical Development | Reveal Email/Phone |
7 | Chief Technology Officer | Reveal Email/Phone |
8 | Director, Clinical Digital Solutions | Reveal Email/Phone |
9 | Chief Quality Officer | Reveal Email/Phone |
10 | CFO & Chief Business Officer | Reveal Email/Phone |
Immunomedics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Immunomedics?
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.
keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power$30M
Total Funding
120
Number of Employees
$34.6M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immunomedics News
Gilead raised eyebrows in 2020 when it agreed to buy Immunomedics for about $21 billion, a substantial premium for a company that was...
Under a proposed settlement, Gilead Sciences' Immunomedics would shell out $4 million to resolve a lawsuit alleging it violated securities laws...
Immunomedics Inc. investors who say the company misled them about cancer drug data presentations asked a federal judge in New Jersey for...
Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...
12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.7M | 137 | 5% | N/A |
#2 | $35M | 140 | 26% | N/A |
#3 | $60.7M | 335 | -2% | N/A |
#4 | $112.1M | 427 | -2% | N/A |
#5 | $135.4M | 539 | 10% | N/A |
Immunomedics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2004-01-15 | $10.0M | notes | Article | |
2005-04-28 | $36.7M | Undisclosed | Multiple | Article |
2014-05-05 | $30.2M | Undisclosed | Article | |
2015-02-09 | $96.4M | Undisclosed | Goldman, Sachs & Co. | Article |
2017-05-08 | $125.0M | Undisclosed | Article |